{"database": "lobbying", "table": "lobbying_activities", "rows": [[3015614, "f209773c-e70d-4977-ad4d-b4a84a4c1fa1", "Q2", "ERVIN GRAVES STRATEGY GROUP, LLC", 13836, "EMERGENT BIOSOLUTIONS INC.", 2023, "second_quarter", "DIS", "\"Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield State opioid response (SOR) Grant funding NDAA for Fiscal Year 2024 - provisions related to biological and chemical defense and access to naloxone \"", "Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2023-07-19T13:14:13-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3015614"], "units": {}, "query_ms": 0.42175501585006714, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}